Arbutus Biopharma provided its 2025 corporate objectives and a financial update, highlighting plans to advance its lead chronic hepatitis B (cHBV) candidate. The company intends to initiate a Phase 2b clinical trial for imdusiran in the first half of 2025.
This decision follows meaningful functional cure rates and immune activation observed in cHBV patients treated with imdusiran, interferon, and nucleos(t)ide analogue therapy in the IM-PROVE I Phase 2a clinical trial. The company believes imdusiran is differentiated from other RNAi therapeutics in development for HBV.
Arbutus also reported a strong financial position, with a cash runway projected through Q1 2028. This projection assumes the receipt of contractual milestones anticipated from Qilu Pharmaceutical.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.